Pharmacyclics Gets $150M Up Front from J&J for Btk Inhibitor
Hematologic cancers always grab the spotlight at the American Society of Hematology (ASH) annual meeting, which kicked off this weekend, but Pharmacyclics Inc. got a head start last week by announcing a $975 million deal with Janssen Biotech Inc. for Phase II hematologic cancer drug PCI-32765.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST